Talphera Q1 net loss $2.6M; NEPHRO CRRT study enrollment progressing

TALPHERA, INC.

Net loss of $2.6M ($0.04 per share) in Q1 2026, flat vs Q1 2025.
Cash and investments $21.1M as of March 31, 2026.
Combined R&D and SG&A expenses $3.9M, up from $2.9M YoY due to higher Niyad development costs.
NEPHRO CRRT study enrollment exceeded 50% milestone; completion expected in 2026.
Closed $4.1M third tranche of private placement upon hitting 35-patient enrollment milestone.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.